Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1989 1
1993 1
1994 1
1999 1
2001 1
2002 2
2005 1
2006 1
2007 1
2008 1
2009 3
2010 1
2011 5
2012 4
2013 5
2014 3
2015 3
2016 2
2017 2
2018 7
2019 7
2020 7
2021 4
2022 10
2023 2
2024 2
2025 3
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.
Li Z, You Y, Griffin N, Feng J, Shan F. Li Z, et al. Int Immunopharmacol. 2018 Aug;61:178-184. doi: 10.1016/j.intimp.2018.05.020. Epub 2018 Jun 7. Int Immunopharmacol. 2018. PMID: 29885638 Review.
Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to eliminate addiction in order to maintain a normal life and prevent or reduce relapse. In recent years, there have been some novel and signi …
Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to …
Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.
Toljan K, Vrooman B. Toljan K, et al. Med Sci (Basel). 2018 Sep 21;6(4):82. doi: 10.3390/medsci6040082. Med Sci (Basel). 2018. PMID: 30248938 Free PMC article. Review.
Low-dose naltrexone (LDN), considered in a daily dose of 1 to 5 mg, has been shown to reduce glial inflammatory response by modulating Toll-like receptor 4 signaling in addition to systemically upregulating endogenous opioid signaling by transient opio …
Low-dose naltrexone (LDN), considered in a daily dose of 1 to 5 mg, has been shown to reduce glial inflammatory …
Low-dose naltrexone's utility for non-cancer centralized pain conditions: a scoping review.
Rupp A, Young E, Chadwick AL. Rupp A, et al. Pain Med. 2023 Nov 2;24(11):1270-1281. doi: 10.1093/pm/pnad074. Pain Med. 2023. PMID: 37302106 Free PMC article.
BACKGROUND: At low doses, naltrexone (LDN) has been shown to modulate inflammation through the interruption of microglial cell activation within the central nervous system. ...
BACKGROUND: At low doses, naltrexone (LDN) has been shown to modulate inflammation through the interruption of microglial cell …
Low Dose Naltrexone for Refractory Cancer Pain: Case Series of Initial Safety and Effectiveness.
Malik A, Ye A, Chung M. Malik A, et al. J Pain Symptom Manage. 2025 Dec;70(6):e492-e497. doi: 10.1016/j.jpainsymman.2025.08.015. Epub 2025 Aug 21. J Pain Symptom Manage. 2025. PMID: 40849024
CONTEXT: Low dose naltrexone (LDN) has been utilized off-label for chronic non-cancer pain; its benefits in treating cancer-related pain remain unclear. ...CONCLUSION: Early follow-up indicates potential benefits for patients with refractory …
CONTEXT: Low dose naltrexone (LDN) has been utilized off-label for chronic non-cancer pain; its benefits in trea …
Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy.
Ciwun M, Tankiewicz-Kwedlo A, Pawlak D. Ciwun M, et al. Cancers (Basel). 2024 Mar 21;16(6):1240. doi: 10.3390/cancers16061240. Cancers (Basel). 2024. PMID: 38539570 Free PMC article. Review.
Low-dose naltrexone (LDN) exhibits antagonistic action against the opioid growth factor receptor (OGFr), whose signaling is associated with the survival, proliferation, and invasion of cancer cells. ...Numerous studies on in vitro and in vivo models pr …
Low-dose naltrexone (LDN) exhibits antagonistic action against the opioid growth factor receptor (OGFr), whose signalin …
Naltrexone at low doses (LDN) and its relevance to cancer therapy.
Liu WM, Dalgleish AG. Liu WM, et al. Expert Rev Anticancer Ther. 2022 Mar;22(3):269-274. doi: 10.1080/14737140.2022.2037426. Epub 2022 Feb 7. Expert Rev Anticancer Ther. 2022. PMID: 35107043 Free article. Review.
It was noted that in certain patients being treated with naltrexone for an opioid addiction many reported significant secondary benefit when being weaned off naltrexone. This group of patients had chronic inflammatory and autoimmune conditions and reported improveme …
It was noted that in certain patients being treated with naltrexone for an opioid addiction many reported significant secondary benef …
Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway.
Liu N, Yan L, Shan F, Wang X, Qu N, Handley MK, Ma M. Liu N, et al. Transl Oncol. 2021 Apr;14(4):101028. doi: 10.1016/j.tranon.2021.101028. Epub 2021 Feb 1. Transl Oncol. 2021. PMID: 33540155 Free PMC article.
The incidence of cervical cancer is increasing annually worldwide. Low-dose naltrexone (LDN) has been reported to delay tumor progression, but the mechanism remains unclear. Here, we found that low-dose naltrexone could upregulate …
The incidence of cervical cancer is increasing annually worldwide. Low-dose naltrexone (LDN) has been reported t …
Low Dose Naltrexone in Dermatology.
Jaros J, Lio P. Jaros J, et al. J Drugs Dermatol. 2019 Mar 1;18(3):235-238. J Drugs Dermatol. 2019. PMID: 30909326
Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide range of conditions including Crohn's disease, fibromyalgia, major depressive disorder, cancer, chronic regional pain syndrome, Charc …
Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide …
Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo.
Liu N, Ma M, Qu N, Wang R, Chen H, Hu F, Gao S, Shan F. Liu N, et al. Int Immunopharmacol. 2020 Sep;86:106718. doi: 10.1016/j.intimp.2020.106718. Epub 2020 Jun 22. Int Immunopharmacol. 2020. PMID: 32585612
The metastasis of cervical cancer has always been a clinical challenge. We investigated the effects of low-dose naltrexone (LDN) on the epithelial mesenchymal transition of cervical cancer cells in vitro as well as its influence on macrophage po …
The metastasis of cervical cancer has always been a clinical challenge. We investigated the effects of low-dose nalt …
77 results